Alzheimer’s Drug Shows Promise in Early Results of Study

September 28, 2022by Tom Murphy, Associated Press
Alzheimer’s Drug Shows Promise in Early Results of Study
Eisai corporate headquarters.

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study.

Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s.

The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. Patients were monitored using a scale that measures how they do in areas like memory, judgement, problem solving and personal care.

Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. It also plans to publish its findings in a peer-reviewed medical journal.

The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Eisai and Biogen will co-promote the drug.

The initial results appear to be “quite robust” and will likely support regulatory approval, Mizuho Securities analyst Graig Suvannavejh said in a research note.

A statement from the Alzheimer’s Association called the findings the most encouraging to date for potential treatments of the underlying disease causes.

Alzheimer’s is a progressive neurological disease with no known cure. Long-standing treatments on the market just manage symptoms, and researchers don’t fully understand what causes the disease.

Last year, Biogen’s Aduhelm became the first new Alzheimer’s drug introduced in nearly two decades. But it has largely flopped after debuting with a price tag of $56,000 annually, which Biogen later slashed.

Doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage over the drug’s high price tag and uncertain benefit.

Like Aduhelm, lecanemab, which Eisai developed and ran through clinical trials, seeks to remove a protein called beta-amyloid from the brain.

But Eisai executives say lecanemab focuses more on floating clumps of the protein before it forms a plaque, which is what Aduhelm targets.

Eli Lilly and Co. also is developing a potential treatment, donanemab, that helps clear the protein.

Shares of Cambridge, Massachusetts-based Biogen Inc. jumped more than 50% in premarket trading Wednesday morning to top $300. The stock had largely tumbled since Aduhelm’s debut last year.

Shares of Indianapolis-based Eli Lilly and Co. were up 8%.

A+
a-

In The News

Health

Voting

Health

May 24, 2024
by Dan McCue
Drowning Deaths On the Rise in the United States

WASHINGTON — After decades of decline, drowning deaths are once again on the rise in the United States, according to... Read More

WASHINGTON — After decades of decline, drowning deaths are once again on the rise in the United States, according to a new Vital Signs study by the Centers for Disease Control and Prevention. Over 4,500 people died due to drowning each year from 2020 to 2022,... Read More

HPV Vaccines Prevent Cancer in Men as Well as Women, New Research Suggests

New research suggests the HPV vaccine is preventing cancer in men, as well as in women, but fewer boys than... Read More

New research suggests the HPV vaccine is preventing cancer in men, as well as in women, but fewer boys than girls are getting the shots in the United States. The HPV vaccine was developed to prevent cervical cancer in women and experts give it credit, along... Read More

Black Americans Underrepresented in Residential Care Communities, AP/CNHI News Analysis Finds

Norma Upshaw was living alone south of Nashville when her doctor said she needed to start in-home dialysis. Her closest... Read More

Norma Upshaw was living alone south of Nashville when her doctor said she needed to start in-home dialysis. Her closest family lived 40 miles away, and they’d already scrambled once when the independent senior living facility the 82-year-old had called home — a community of largely... Read More

May 22, 2024
by Dan McCue
CDC Identifies Second Human Bird Flu Case in US

ATLANTA — A Michigan farmworker became the second individual in the United States this year confirmed to have contracted the... Read More

ATLANTA — A Michigan farmworker became the second individual in the United States this year confirmed to have contracted the bird flu after exposure to infected livestock, the Centers for Disease Control and Prevention announced Wednesday. The individual had only mild symptoms of infection with the... Read More

May 22, 2024
by Dan McCue
Senators Say State Abortion Ban Causing Exodus of Women’s Health Care Providers

WASHINGTON — A trio of Democratic senators assailed abortion bans in Republican-led states on Tuesday, pointing to a new report... Read More

WASHINGTON — A trio of Democratic senators assailed abortion bans in Republican-led states on Tuesday, pointing to a new report that suggests those laws are forcing women’s health care providers to turn away patients, shut down practices and abandon those states altogether for fear of prosecution... Read More

May 22, 2024
by Jesse Zucker
Strength Training May Improve Mental Health

WASHINGTON — Do you generally feel good after exercise? It has been well-documented that getting regular physical activity may improve... Read More

WASHINGTON — Do you generally feel good after exercise? It has been well-documented that getting regular physical activity may improve mental health and help decrease symptoms of depression and anxiety, but how does it work? Most research focuses on how cardio exercise impacts mental health. Less... Read More

News From The Well
scroll top